Rahul Ballal
Director/Board Member at AGIOS PHARMACEUTICALS, INC.
Net worth: 447 786 $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jacqualyn Fouse | M | 62 | 7 years | |
| Samuel Kintz | M | 38 | 5 years | |
| Nicholas Benedict | M | - |
Vaderis Therapeutics AG
 Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | - |
| Joseph Lyssikatos | M | 59 | 5 years | |
| Paul Yaworsky | M | - |
Mediar Therapeutics, Inc.
 Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | 5 years |
| Christopher Taylor | M | - | - | |
| Anish Patel | M | 43 | 5 years | |
| Sarah Gheuens | M | 45 | 5 years | |
| Kaye Foster-Cheek | F | 64 | 10 years | |
| Andrew Phillips | M | 53 | 1 years | |
| Judit Anido Folgueira | M | - |
Northern Biologics, Inc.
 Northern Biologics, Inc. Hospital/Nursing ManagementHealth Services Northern Biologics Inc. operates as an early-stage biologics company. It develops a portfolio of antibody-based therapeutics for oncology and fibrosis. The company was founded by Jason Moffat, Rob Rottapel, Benjamin G. Neel, Sachdev Sidhu, Brad Wouters, and Stefan Larson in June 2014 and is headquartered in Toronto, Canada. | 7 years |
| Mika Derynck | M | 61 | 1 years | |
| Cynthia Smith | F | 55 | 2 years | |
| Jeffrey Capello | M | 69 | 1 years | |
| Brian Goff | M | 55 | 2 years | |
| Jake Bauer | M | 45 | 1 years | |
| David Scadden | M | 71 | 7 years | |
| Pierre Saint-Mezard | M | - |
Vaderis Therapeutics AG
Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | - |
| Richard Heyman | M | 66 | 1 years | |
| Damien Picard | M | - |
Vaderis Therapeutics AG
Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | - |
| Rishi Gupta | M | 46 | 1 years | |
| May Kin Ho | M | 71 | 9 years | |
| Peter D. Parker | M | 73 |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | - |
| David de Graaf | M | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | - |
| Nick Williams | M | - |
Vaderis Therapeutics AG
Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | - |
| Cecilia Jones | F | 49 | 2 years | |
| Ellen Lopresti | F | - | 7 years | |
| Joan S Brugge | M | - | - | |
| T. Washburn | M | 43 | - | |
| Benjamin Hohl | M | 35 | 1 years | |
| Helen Collins | M | 62 | 1 years | |
| Galya Blachman | M | 47 | - | |
| Catherine Owen | F | - | 1 years | |
| Brian Hubbard | M | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | - |
| Nandita Shangari | M | 43 |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | 1 years |
| Tsveta Milanova | F | 47 | 1 years | |
| Clive Patience | M | 60 | 7 years | |
| Giovanni Mariggi | M | 39 |
Vaderis Therapeutics AG
Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | - |
| Andreas Jurgeit | M | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | - |
| Michael Baran | M | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | 3 years |
| Hedvika Lazar | F | - |
Vaderis Therapeutics AG
Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | - |
| Maina Bhaman | M | 52 |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | 1 years |
| Simon Sturge | M | 65 |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | 3 years |
| Jim Burns | M | 46 | 8 years | |
| Charlie Newman | F | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Andrew Schwab | M | 53 | 7 years | |
| Bradley Bolzon | M | 64 | 7 years | |
| C. Merrifield | F | 73 | 7 years | |
| John Maraganore | M | 60 | 13 years | |
| Philip Vickers | M | 64 |
Northern Biologics, Inc.
Northern Biologics, Inc. Hospital/Nursing ManagementHealth Services Northern Biologics Inc. operates as an early-stage biologics company. It develops a portfolio of antibody-based therapeutics for oncology and fibrosis. The company was founded by Jason Moffat, Rob Rottapel, Benjamin G. Neel, Sachdev Sidhu, Brad Wouters, and Stefan Larson in June 2014 and is headquartered in Toronto, Canada. | 3 years |
| Sandy Mahatme | M | 59 | - | |
| Lisa Davidson | F | 58 | 6 years | |
| Jonathan Biller | M | 61 | 3 years | |
| Paul Clancy | M | 62 | 10 years | |
| Rafaèle Elisabeth Tordjman | M | 54 | 5 years | |
| Holly Manning | F | - | 6 years | |
| Heath Lukatch | M | 56 | 9 years | |
| Elaine Jones | M | 69 | 5 years | |
| Michael Gray | M | 53 | 4 years | |
| Scott Canute | M | 63 | 6 years | |
| Mittie Doyle | M | 59 | 1 years | |
| Kerri-Ann Millar | F | 54 | 3 years | |
| Jessica Rennekamp | F | - | 4 years | |
| Angus M. Sinclair | M | - |
Northern Biologics, Inc.
Northern Biologics, Inc. Hospital/Nursing ManagementHealth Services Northern Biologics Inc. operates as an early-stage biologics company. It develops a portfolio of antibody-based therapeutics for oncology and fibrosis. The company was founded by Jason Moffat, Rob Rottapel, Benjamin G. Neel, Sachdev Sidhu, Brad Wouters, and Stefan Larson in June 2014 and is headquartered in Toronto, Canada. | 3 years |
| Darlene Deptula-Hicks | F | 66 |
Northern Biologics, Inc.
Northern Biologics, Inc. Hospital/Nursing ManagementHealth Services Northern Biologics Inc. operates as an early-stage biologics company. It develops a portfolio of antibody-based therapeutics for oncology and fibrosis. The company was founded by Jason Moffat, Rob Rottapel, Benjamin G. Neel, Sachdev Sidhu, Brad Wouters, and Stefan Larson in June 2014 and is headquartered in Toronto, Canada. | - |
| J. Christopher Prue | M | - | - | |
| Judy Carmody | M | 57 | - | |
| Joseph Vittiglio | M | 52 | - | |
| Arthur Fratamico | M | 58 | 2 years | |
| Fred Driscoll | M | 74 | 4 years | |
| Robert Blanks | M | 64 | 3 years | |
| Kerry Wentworth | F | 51 | 7 years | |
| Richa Poddar | F | - | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 63 | 86.30% |
| Switzerland | 6 | 8.22% |
| Canada | 4 | 5.48% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Rahul Ballal
- Personal Network
